Cronos Group Inc(CRON) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:49 PM ET (Korea 9/12 05:49)
Full metrics table
| Index | - | P/E | 17.05 | EPS (ttm) | 0.18 | Insider Own | 49.82% | Shs Outstand | 370.7M | Perf Week | -3.68% |
| Market Cap | 1.16B | Forward P/E | 27.71 | EPS next Y | -28.04% | Insider Trans | - | Shs Float | 184.9M | Perf Month | -0.95% |
| Enterprise Value | 0.41B | PEG | - | EPS next Q | 0.03 | Inst Own | 14.45% | Short Float | 1.76% | Perf Quarter | 14.18% |
| Income | 0.07B | P/S | 6.46 | EPS this Y | 887.5% | Inst Trans | -0.54% | Short Ratio | 2.8 | Perf Half Y | 26.1% |
| Sales | 0.18B | P/B | 1.09 | EPS next 5Y | - | ROA | 5.94% | Short Interest | 3.24M | Perf YTD | 19.39% |
| Book/sh | 2.88 | P/C | 1.45 | EPS past 3/5Y | 61.97% 34.75% | ROE | 6.51% | 52W High | -12.96% ($3.61) | Perf Year | 21.71% |
| Cash/sh | 2.16 | P/FCF | 23.14 | Sales past 3/5Y | 19.11% 25.7% | ROIC | 6.54% | 52W Low | 37.72% ($2.28) | Perf 3Y | 30.83% |
| Dividend Est. | - | EV/EBITDA | 39.56 | EPS Y/Y TTM | 276.99% | Gross Margin | 44.99% | Volatility(W/M) | 2.24% 3.42% | Perf 5Y | -48.78% |
| Dividend TTM | - | EV/Sales | 2.29 | Sales Y/Y TTM | 37.46% | Oper. Margin | -2.19% | ATR (14) | 0.1 | Perf 10Y | 715.58% |
| Dividend Ex-Date | - | Quick Ratio | 15.25 | EPS Q/Q | 182.93% | Profit Margin | 39.08% | RSI (14) | 46.39 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.18 | Sales Q/Q | 58.44% | SMA20 | -4.43% ($3.29) | Beta | 0.91 | Target Price | $3.52 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | 3.77% ($3.03) | Rel Volume | 0.61 | Prev Close | $3.16 |
| Employees | 610 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 800% 19.93% | SMA200 | 14.23% ($2.75) | Avg Volume(3M) | 1.16M | Price | $3.14 |
| IPO | 2016/7/12 | Option/Short | Yes/Yes | Trades | 2891 | Volume | 707,783 | Change | -0.63% |
Company
CRON is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🌿 Cronos Group (CRON) is a Canada-based company that cultivates, manufactures, and sells cannabis and cannabis-derived products. It focuses on two major markets: the Israeli medical market and the Canadian adult-use (recreational) market, operating a diversified product portfolio that includes dried flower, extracts, and edible products. The company has established a strong presence through its Peace Naturals brand in the Israeli medical cannabis market and its Spinach brand in the Canadian edible products market.
Over the past 1 year, roughly in the middle
13% below its 1-year high.
CRON has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +887.5% this year.
Tap to view numbers
The stock looks undervalued
Trading at 17.1 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +30.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 14.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
TOKE 0.05%
YOLO 0.04%
CNBS 0.00%
DFIS 0.00%
ONEQ 0.00%It ranks #4 in the industry
Based on market cap of $1B.
CRON $1B PER 17.1
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is CRON?
CRON belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of CRON?
The market cap of CRON is approximately $1.2B, ranking 2,529 within its sector.
What is the P/E ratio of CRON?
CRON has a P/E ratio of approximately 17.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for CRON?
CRON has recorded a 52-week high of $3.61 and a low of $2.28.
